[Oral capecitabine therapy: experience and developments at the Milano Cancer Institute].
Longo
Flavia
F
Oncologia Medica, Policlinico Umberto I, Roma.
Mansueto
Giovanni
G
D000047:Academies and Institutes; D000284:Administration, Oral; D000367:Age Factors; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D000069287:Capecitabine; D017024:Chemotherapy, Adjuvant; D017326:Clinical Trials, Phase III as Topic; D003226:Congresses as Topic; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives; D006801:Humans; D007558:Italy; D015337:Multicenter Studies as Topic; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil